by University of Southern California Credit: Pixabay/CC0 Public Domain Two stories dominated Alzheimer’s news this year: The FDA’s approval of Leqembi, the first drug to slow progression of the disease, and a surprising study showing that mild cognitive impairment is wildly underdiagnosed. “For mild cognitive impairment, or MCI, caused by Alzheimer’s disease, the earlier you treat...
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IMAGE: CARLOS CRUCHAGA, PH.D., WASHINGTON UNIVERSITY SCHOOL OF MEDICINE CREDIT: WASHINGTON UNIVERSITY SCHOOL OF MEDICINE A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets. The potential targets are...
